HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Danni Yu Selected Research

LY3022856

10/2016Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Danni Yu Research Topics

Disease

9Neoplasms (Cancer)
10/2022 - 08/2015
6Fatigue
01/2021 - 05/2019
4Diarrhea
01/2021 - 01/2020
4Nausea
01/2021 - 01/2020
2Neoplasm Metastasis (Metastasis)
01/2021 - 10/2016
2Melanoma (Melanoma, Malignant)
01/2021 - 01/2020
2Exanthema (Rash)
01/2021 - 01/2020
2Anorexia
01/2021 - 01/2021
2Chronic Disease (Chronic Diseases)
11/2020 - 05/2019
1Urologic Neoplasms (Urological Cancer)
10/2022
1Carcinoma (Carcinomatosis)
10/2022
1Syncope (Fainting)
01/2022
1Renal Cell Carcinoma (Grawitz Tumor)
01/2022
1Microsatellite Instability
12/2021
1Dehydration (Water Stress)
10/2021
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2021
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021
1Fever (Fevers)
01/2021
1Hypothyroidism
01/2021
1Pruritus (Itching)
01/2021
1Vomiting
01/2021
1Breast Neoplasms (Breast Cancer)
11/2020
1Prostatic Neoplasms (Prostate Cancer)
11/2020
1Dermatitis
01/2020
1Colorectal Neoplasms (Colorectal Cancer)
10/2016
1Brain Injuries (Brain Injury)
01/2012
1Traumatic Brain Injuries (Traumatic Brain Injury)
01/2012

Drug/Important Bio-Agent (IBA)

4Pharmaceutical PreparationsIBA
01/2020 - 08/2015
3Lipase (Acid Lipase)FDA Link
01/2022 - 11/2020
2NivolumabIBA
10/2022 - 01/2022
2bempegaldesleukinIBA
10/2022 - 01/2022
2Immune Checkpoint InhibitorsIBA
01/2022 - 12/2021
2LY3321367IBA
12/2021 - 01/2021
2LY3300054IBA
12/2021 - 01/2021
2Monoclonal AntibodiesIBA
01/2021 - 10/2016
2LY3022855IBA
01/2021 - 11/2020
2abemaciclibIBA
01/2021 - 01/2021
2Aquaporins (Water Channels)IBA
01/2020 - 01/2020
2Acute-Phase Proteins (Acute-Phase Protein)IBA
01/2020 - 01/2020
2Castor Oil (Oil, Castor)IBA
01/2020 - 01/2020
1Biomarkers (Surrogate Marker)IBA
10/2022
1ProdrugsIBA
10/2022
1Cisplatin (Platino)FDA LinkGeneric
10/2022
1perovskiteIBA
10/2021
1LY3023414IBA
01/2021
1crenigacestatIBA
01/2021
1merestinibIBA
01/2021
1RamucirumabIBA
01/2021
1AmylasesFDA Link
01/2021
1Antineoplastic Agents (Antineoplastics)IBA
01/2021
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2021
1LigandsIBA
01/2021
1Phosphotransferases (Kinase)IBA
01/2021
1Macrophage Colony-Stimulating Factor Receptor (Receptor, Macrophage Colony Stimulating Factor)IBA
01/2021
1Creatine Kinase (Creatine Phosphokinase)IBA
11/2020
1Drug CombinationsIBA
11/2020
1Antiviral Agents (Antivirals)IBA
11/2020
1Carrier Proteins (Binding Protein)IBA
01/2020
1LY3009120IBA
01/2020
1PhytochemicalsIBA
01/2020
1Loperamide (Imodium)FDA LinkGeneric
01/2020
1Immunoglobulin G (IgG)IBA
10/2016
1LY3022856IBA
10/2016
1Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
10/2016
1PolymersIBA
08/2015
1graphene oxideIBA
08/2015
1MicroRNAs (MicroRNA)IBA
01/2012

Therapy/Procedure

6Therapeutics
10/2022 - 08/2015
1Drug Therapy (Chemotherapy)
10/2022
1Castration
11/2020
1Highly Active Antiretroviral Therapy (HAART)
05/2019
1Electrodes (Electrode)
08/2015